Chen, BaoQing
Dragomir, Mihnea P.
Yang, Chen
Li, Qiaoqiao
Horst, David
Calin, George A. http://orcid.org/0000-0002-7427-0578
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UH3TR00943-01)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01 CA182905-01, 1R01CA222007-01A1)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (1R01GM122775-01)
U.S. Department of Defense (CA160445P1)
National Natural Science Foundation of China (81902462)
Article History
Received: 30 September 2021
Revised: 7 March 2022
Accepted: 7 March 2022
First Online: 13 April 2022
Competing interests
: G.A.C. is the scientific founder of Ithax Pharmaceuticals. All other authors declare no conflict of interest. G.A.C. is the editorial board member of Signal Transduction and Targeted Therapy, but he has not been involved in the process of the manuscript handling.